According to The Insight Partners’ Latest Study on “Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028″ Focuses COVID-19 Impact and Global Analysis By Drug Class (Steroids, Antidepressants, Anti-Seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)
“Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Class and Distribution Channel,” the market is expected to grow from US$ 813.48 million in 2021 to US$ 1,174.26 million by 2028; it is estimated to grow at a CAGR of 5.4% during 2021–2028.
Download PDF Sample Copy at:
The growth of the chemotherapy-induced peripheral neuropathy market is mainly driven by an increase in the prevalence of cancer and a rising preference for chemotherapy. Additionally, the growing number of clinical trials for chemotherapeutic drugs is likely to emerge as a significant trend in the market during the forecast period. However, the lack of consolidated guidelines for chemotherapy hampers the chemotherapy-induced peripheral neuropathy market growth.
Leading Players Outlook:
The chemotherapy induced peripheral neuropathy market is majorly comprised of top players involving Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the chemotherapy induced peripheral neuropathy market:
Mar-2022: Asahi Kasei Pharma Open new window announced that study drug administration has begun for the first patient in the Japan-US international phase 1 study of ART-123 (generic name: thrombomodulin alfa; marketed as Recomodulin Injection in Japan)1) for the prevention of sensory symptoms of chemotherapy-induced peripheral neuropathy (CIPN) being performed jointly with Veloxis Pharmaceuticals, Inc., wholly-owned subsidiary of Asahi Kasei Corp. (SENSEible mCRC Study,2) in the future “the Study”)
Jan-2021: Novaremed AG, a clinical-stage Swiss biopharmaceutical company, signed a $50 million capital commitment agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private alternative investment group, in January 2021. Novaremed receives a $50 million investment from Global Emerging Markets
Have a Call with Analyst:
April-2021: WEX Pharmaceuticals Inc. announced that two clinical trials on tetrodotoxin (TTX) as a therapeutic agent had been published in a special issue of the Toxins Journal. The cardiac safety study “Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults” was included in the special edition of the Toxins Journal, as was the study “Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding WEX
Jul-2021: Kineta Inc announced that the first participant in a Phase 1 multiple ascending dose (MAD) clinical trial of KCP506, an investigational, first-in-class nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain, had been dosed successfully. The first participant in Kineta’s Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 has been dosed
The chemotherapy-induced peripheral neuropathy market is segmented on the basis of drug class, distribution channel, and geography.
The market, by drug class, is segmented into steroids, antidepressants, anti-seizures, and narcotics.
The chemotherapy-induced peripheral neuropathy market, based on distribution channel, is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
By geography, the chemotherapy-induced peripheral neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Buy Report at:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi